Abstract 278P
Background
Radical chemoradiation (CTRT) is the standard of care in locally advanced head and neck cancer (LAHNC). For mitigating the normal tissue toxicity, many techniques have been explored and utilized, including IMRT and adaptive radiotherapy (ART). Significant anatomical variations occur during CTRT due to weight loss and tumor and normal tissue changes. In the present study, serial changes in parotid volumes were assessed with weekly scans along with dosimetric correlation.
Methods
This prospective, single-institutional study, included 12 patients with LA HNC receiving CTRT. All underwent CT simulation (CT sim) followed by weekly rescans from week 1 to 6. Target volumes and organs at risk, including right & left parotids (RP & LP) were recontoured in all rescans after fusion with the CT sim. Dose overlay was done in each rescan to generate a hybrid plan to study corresponding dosimetric variations. Volume changes in parotids were reported as percentage change from the baseline.
Results
In CT sim, right parotid volumes (RPV) ranged from 15.7 - 44.2 cc (mean - 24.1 SD – 7.9) and left parotid volume (LPV) from 12.2 - 47.1 cm3 (mean 22.8, SD -9.9). Mean % reduction in RPV in week 1, 2, 3, 4, 5 and 6 were 14.2% (p=0.003), 17.1% (p=0.007), 21.8% (p < 0.001), 25.6% (p < 0.001), 30% (p < 0.001), 32.1% (p < 0.001) respectively. Mean % reduction in LPV in week 1, 2, 3, 4, 5 and 6 were 8.9% (p=0.016), 14.5% (p=0.012), 17.7% (p=0.001), 20.1% (p=0.002), 24.9% (p < 0.001), 28.9% (p < 0.001) respectively. LP D mean showed a significant increase in week 3 (4.6% from baseline, p=0.019) and week 6 (7.6% from baseline, p=0.034). Both parotids showed a significant reduction in V26 Gy with 12.3%, 15.1%, 18.9%, 22.9%, 25.7%, 27.0%, respectively, from week 1 to 6 in RP and 7.3%, 15.7%, 13.8%, 16.8%, 20.8%, 24.1%, respectively, in LP.
Conclusions
Parotid volume shrinkage started from the 1st week. At the end of CTRT, there was 30-32% reduction in volume. V26 Gy of both parotids showed significant reduction during CTRT. Studies focusing on parotid volume changes shows wide variations in volume reduction ranging from 13% to 50% at the end of treatment. These parotid volume changes during RT need to be incorporated while doing ART in LAHNC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uttarakhand.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session